Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer

Active, not recruitingOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

March 31, 2026

Conditions

Advanced Breast Cancer

Interventions

DRUG

Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety

Patients aged ≥18 years with advanced HR-positive breast cancer who received CDK4/6 inhibitors at six hospitals in China were included in this study.

Trial Locations (1)

Jiangsu Provincial People's Hospital, Nanjing

All Listed Sponsors

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT06926088 - Impact of BMI on CDK4/6 Inhibitors Efficacy and Safety in Advanced Breast Cancer | Biotech Hunter | Biotech Hunter